FİNANSAL TOKSİSİTE: KANSER BAKIMINDA YENİ BİR YAN ETKİ

Yıl 2021, Cilt: 24 Sayı: 3, 651 - 680, 29.09.2021

Duygu Ürek , Özgür Uğurluoğlu

Öz

Kanser ile mücadele açısından son yıllarda yaşanan gelişmeler hastalar, aileleri ve tıp camiası için büyük umutlar ve heyecanlar yaratmaktadır. Ancak bu onkolojik yeniliklerin beraberinde getirdiği yüksek fiyat etiketi, tedavilerin hem bireysel hem de sağlık sistemi bazında karşılanabilirliği konusunda duyulan endişelerin giderek artmasına yol açmaktadır. Bu endişeler doğrultusunda üçüncü taraf ödeyiciler, kanser tedavisi maliyetlerinin önemli bir kısmını hastalara aktarma yoluna gitmektedir. Gerçekleşen bu maliyet paylaşımı kanser hastalarının daha fazla cepten harcama yapmasına ve finansal anlamda daha fazla sıkıntı yaşamasına neden olmaktadır. Kanser teşhisi ve tedavisinin hastalar üzerinde yarattığı bu ekonomik sıkıntı finansal toksisite olarak adlandırılmaktadır. Bu çalışmanın amacı; son zamanlarda büyük bir endişe konusu haline gelen ve kanserin yeni bir yan etkisi olarak kabul edilen finansal toksisite sorununu tüm yönleriyle ortaya koymaktır. Bu kapsamda; ilgili literatür taranarak sorunun kavramsal çerçevesi çizilmiş ve dünya genelinde farklı ülkelerden elde edilen araştırma sonuçları eşliğinde Türkiye de dahil olmak üzere çeşitli ülkelerde kanser hastalığı ile mücadele eden hastaların finansal toksisiteye maruziyeti, bu sorun ile ilişkili risk faktörleri ve bu sorunun hasta sonuçları üzerinde yarattığı etkiler kapsamlı olarak değerlendirilmiştir. Kanser tedavisinin finansal toksisitesi görece olarak yeni bir araştırma alanıdır. Sağlık sistemleri, geri ödeme modelleri ve tıbbi müdahaleler gelişmeye devam ettikçe, finansal toksisite kanser hastalarına ilişkin sonuçlar üzerinde önemli bir rol oynamaya devam edecektir. Bu nedenle bu konuda daha fazla çalışma yapılmasına ihtiyaç duyulmaktadır.

Anahtar Kelimeler

Kanser hastalığı, Finansal toksisite, Cepten harcamalar

FINANCIAL TOXICITY: A NEW SIDE EFFECT IN CANCER CARE

Öz

Developments in the fight against cancer in recent years generate great hopes and excitement for patients, their families and the medical community. However, the high price tag brought about by these oncological innovations has led to an increasing concern about the affordability of treatments on both individual and health system levels. In line with these concerns, third-party payers prefer to shift a significant portion of cancer treatment costs to patients. This cost sharing results in considerable out-of-pocket expenses and financial hardship among patients with cancer. This economic hardship caused by cancer diagnosis and treatment on patients is called financial toxicity. The aim of this study is to reveal all aspects of the financial toxicity problem, which has become a major concern and is considered a new side effect of cancer recently. In this context, the conceptual framework of the problem has been generated by scanning relevant literature and exposure of patients struggling with cancer to financial toxicity in various countries, including Turkey, risk factors associated with this problem and effects’ of this problem on patient outcomes have been extensively evaluated. The financial toxicity of cancer treatment is a relatively new research area. As health systems, reimbursement models and medical interventions continue to evolve, financial toxicity will continue to play an important role in outcomes for cancer patients. Therefore, there is a need for more studies on this subject.

Anahtar Kelimeler

Cancer, Financial toxicity, Out-of-pocket costs

Kaynakça

• American Society of Clinical Oncology (ASCO). (2009). Managing the cost of cancer care: Practical guidance for patients and families: Practical Guidance for Patients and Families. American Society of Clinical Oncology, Alexandria, VA.
• Arozullah, A. M., Calhoun, E. A., Wolf, M., Finley, D. K., Fitzner, K. A., Heckinger, E. A., Gorby, N. S., Schumock, G. T., & Bennett, C. L. (2004). The financial burden of cancer: Estimates from a study of insured women with breast cancer. J Support Oncol, 2(3), 271-278.
• Atasever, M. (2014). Türkiye sağlık hizmetlerinin finansmanı ve sağlık harcamalarının analizi 2002-2013 dönemi. Ankara: Sağlık Bakanlığı Yayınları.
• Atun, R., Aydın, S., Chakraborty, S., Sümer, S., Aran, M., Gürol, I., Nazlıoğlu, S., Özgülcü, Ş., Aydoğan, Ü., Ayar, B., Dilmen, U., & Akdağ, R. (2013). Universal health coverage in Turkey: Enhancement of equity. Lancet, 382(9886), 65-99.
• Azzani, M., Roslani, A. C., & Su, T. T. (2015). The perceived cancer-related financial hardship among patients and their families: A systematic review. Support Care Cancer, 23(3), 889-898.
• Azzani, M., Yahya, A., Roslani, A. C., & Su, T. T. (2017). Catastrophic health expenditure among colorectal cancer patients and families: A case of Malaysia. Asia Pacific Journal of Public Health, 29(6), 485-494.
• Bach, P. B. (2009). Limits on Medicare’s ability to control rising spending on cancer drugs. The New England Journal of Medicine, 360(6), 626-633.
• Barbaret, C., Brosse, C., Rhondali, W., Ruer, M., Monsarrat, L., Michaud, P., Schott, A. M., Delgado-Guay, M., Bruera, E., Sanchez, S., & Filbet, M. (2017). Financial distress in patients with advanced cancer. Plos One, 12(5): e0176470.
• Beeler, W. H., Bellile, E. L., Casper, K. A., Jaworski, E., Burger, N. J, Malloy, K. M., Spector, M. E., Shuman, A. G., Rosko, A., Stucken, C. L., Chinn, S. B., Dragovic, A. F., Chapman, C. H., Owen, D., Jolly, S., Bradford, C. R., Prince, M. E. P., Worden, F. P., Jagsi, R., Mierza, M. L., & Swiecicki, P. L. (2020). Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. Oral Oncology, 101:104521. doi:10.1016/j.oraloncology.2019.104521.
• Bernard, D. M., Farr, S. L., & Fang, Z. (2011). National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol, 29(20), 2821-2826.
• Bhoo-Pathy, N., Ng, C., Lim, G. C., Tamin, N. S. I., Sullivan, R., Bhoo-Pathy, N. T., Abdullah, M. M., Kimman, M., Subramaniam, S., Saad, M., Taib, N. A., Chang, K., Goh, P., & Yip, C. (2019). Financial toxicity after cancer in a setting universal health coverage: A call for urgent action. Journal of Oncology Practice, 15(6), e537-e546.
• Bouberhan, S., Shea, M., Kennedy, A., Erlinger, A., Stack-Dunnbier, H., Buss, M. K., Moss, L., Nolan, K., Awtrey, C., Dalrymple, J. L., Garrett, L., Liu, F. W., Hacker, M. R., & Esselen, K. M. (2019). Financial toxicity in gynecologic oncology. Gynecologic Oncology, 154(1), 8-12.
• Brill, S. (2013). Bitter Pill: Why medical bills are killing us?. Time, https://time.com/198/ adresinden 01.10.2020 tarihinde erişilmiştir.
• Brown, M. L., Lipscomb, J., & Snyder, C. (2001). The burden of illness of cancer: Economic cost and quality of life. Annu Rev Public Health, 22(1), 91-113.
• Callahan, C., & Brintzenhofeszoc, K. (2015). Financial quality of life for patients with cancer: An exploratory study. Journal of Psychosocial Oncology, 33(4), 377-394.
• Cancer Support Community. (2016). Access to care in cancer 2016: Barriers and challenges. https://www.cancersupportcommunity.org/article/access-care-cancer adresinden 01.10.2020 tarihinde erişilmiştir.
• Carrera, P. M., & Ormond, M. (2015). Current practice in and considerations for personalized medicine in lung cancer: From the patient’s molecular biology to patient values and preferences. Maturitas, 82(1), 94-99.
• Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018). The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin, 68(2), 153-165.
• Carrera, P., & Zafar, S. Y. (2018). Financial toxicity. In I. Olver (Ed.), The MASCC textbook of cancer supportive care and survivorship (2nd ed., pp. 127-143). Springer International Publishing AG, Switzerland.
• Cavalieri, C. C. (2016). Cost of cancer care: Evaluating financial toxicity. Hematology/Oncology Pharmacy Association News, 13(1), 1-26.
• Chan, A., Chiang, Y. Y., Low, X. H., Yap, K. Y. & Ng, R. (2013). Affordability of cancer treatment for aging cancer patients in Singapore: An analysis of health, lifestyle and financial burden. Support Care Cancer, 21(12), 3509-3517.
• Chen, J. E., Lou, V. W., Jian, H., Zhou, Z., Yan, M., Zhu, J., Li, G., & He, Y. (2018). Objective and subjective financial burden and its associations with health-related quality of life among lung cancer patients. Support Care Cancer, 26(4), 1265-1272.
• Chi, M. (2019). The hidden cost of cancer: Helping clients cope with financial toxicity. Clin Soc Work J, 47, 249-257.
• Çakır, Y. (2011). Sağlık hizmetlerinde katılım payı uygulaması ve bu uygulamanın sosyal devlet ilkesi ve sosyal güvenlik hakkı bakımından incelenmesi. Sayıştay Dergisi, 80(Ocak-Mart), 85-105.
• Davis, E., & Fugett, S. (2018). Financial toxicity: Limitations and challenges when caring for older adult patients with cancer. Clinical Journal of Oncology Nursing, 22(6), 43-48.
• de Souza, J. A., & Conti, R. M. (2017). Mitigating financial toxicity among US patients with cancer. JAMA Oncology, 3(6), 765-766.
• de Souza, J. A., & Wong, Y. (2013). Financial distress in cancer patients. J Med Person, 11(2): doi:10.1007/s12682-013-0152-3.
• de Souza, J. A., Grogan, R., & Aschebrook-Kilfoy, B. (2016). Financial toxicity in thyroid cancer – an analysis from the North American thyroid cancer survivorship study. International Journal of Radiation Oncology, Biology, Physics, 94(4), 960.
• de Souza, J. A., Yap, B. J., Hlubocky, F. J., Wroblewski, K., Ratain, M. J., Cella, D., & Daugherty, C. K. (2014). The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer, 120(20), 3245-3253.
• de Souza, J. A., Yap, B. J., Wroblewski, K., Blinder, V., Araújo, F. S., Hlubocky, F. J., Nicholas, L. H., O’Connor, J. M., Brockstein, B., Ratain, M. J., Daugherty, C. K. & Cella, D. (2017). Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the comprehensive score for financial toxicity (COST). Cancer, 123(3), 476-484.
• Deloitte & Türkiye Sigorta Birliği (2015). Tamamlayıcı özel sağlık sigortası: Dünya uygulamalarından örneklerin incelenmesi ve Türkiye için öneriler raporu. https://docplayer.biz.tr/12774940-Tamamlayici-ozel-saglik-sigortasi-dunya-uygulamalarindan-orneklerin-incelenmesi-ve-turkiye-icin-oneriler-raporu.html adresinden 01.01.2021 tarihinde erişilmiştir.
• Department for Professional Employees (DPE) Research Department. (2016). The U.S. health care system: An international perspective. Washington, DC.
• Desai, A., & Gyawali, B. (2020). Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. EClinicalMedicine, 20:100269. doi: 10.1016/j.eclinm.2020.100269.
• Dickman, S., Himmelstein, D. U., & Woolhandler, S. (2017). Inequality and the health-care system in the USA. Lancet, 389(10077), 1431-1441.
• Egestad, H., & Nieder, C. (2015). Undesirable financial effects of head and neck cancer radiotherapy during the initial treatment period. International Journal of Circumpolar Health, 74:26686. doi: 10.3402/ijch.v74.26686.
• Engelgau, M. M., Karan, A., & Mahal, A. (2012). The economic impact of non-communicable diseases on households in India. Globalization and Health, 8:9. doi: 10.1186/1744-8603-8-9.
• Ezeife, D. A., Morganstein, B. J., Lau, S., Law, J. H., Le, L. W., Bredle, J., Cella, D., Doherty, M. K., Bradbury, P., Liu, G., Sacher, A., Shepherd, F. A., & Leighl, N. B. (2019). Financial burden among patients with lung cancer in a publically funded health care system. Clinical Lung Cancer, 20(4), 231-236.
• Fathollahzade, A., Rahmani, A., Dadashzadeh, A., Gahramanian, A., Esfahani, A., Javanganji, L., & Nabiolahi, L. (2015). Financial distress and its predicting factors among Iranian cancer patients. Asian Pac J Cancer Prev, 16(4), 1621-1625.
• Fitzner, K., Oteng-Mensah, F., Donley, P., & Heckinger, E. A. F. (2017). Safety of cancer therapies: At what cost?. Population Health Management, 20(4), 318-328.
• Goldsbury, D. E., Yap, S., Weber, M. F., Veerman, L., Rankin, N., Banks, E., Canfell, K., & O’Connell, D. L. (2018). Health services costs for cancer care in Australia: Estimates from the 45 and up study. Plos One, 13(7): e0201552. https://doi.org/10.1371/journal.pone.0201552.
• Goldstein, D. A. (2017). Financial toxicity in cancer care-edging toward solutions. Cancer, 123(8), 1301-1302.
• Gordon, L. G., Merollini, K. M. D., Lowe, A., & Chan, R., J. (2017a). Financial toxicity – What it is and how to measure it. Cancer Forum, 41(2), 30-35.
• Gordon, L. G., Merollini, K. M. D., Lowe, A., & Chan, R. J. (2017b). A systematic review of financial toxicity among cancer survivors: We can’t pay the co-pay. Patient, 10(3), 295-309.
• Gordon, L. G., Walker, S. M., Mervin, M. C., Lowe, A., Smith, D. P., Gardiner, R. A., & Chambers, S. K. (2017c). Financial toxicity: A potential side effect of prostate cancer treatment among Australian men. European Journal of Cancer Care, 26(1): e12392. doi: 10.1111/ecc.12392.
• Gordon, L. G., Elliott, T. M., Wakelin, K., Leyden, S., Leyden, J., Michael, M., Pavlakis, N., Mumford, J., Segelov, E., & Wyld, D. K. (2020). The economic impact on Australian patients with neuroendocrine tumors. The Patient-Patient-Centered Outcomes Research, 13, 363-373.
• Greenup, R. A., Rushing, C., Fish, L., Hyslop, T., Peppercorn, J. M., Wheeler, S. B., Zafar, Y., Myers, E., & Hwang, E. S. (2018). The costs of breast cancer care: Patient-reported experiences and preferences for transparency. Journal of Clinical Oncology, 36, no. 30_suppl, 207-207. DOI: 10.1200/JCO.2018.36.30_suppl.207.
• Gyawali, B. (2018). Financial toxicity and out of pocket costs. Journal of Thoracic Oncology, 13(10), Supplement, S277. DOI:https://doi.org/10.1016/j.jtho.2018.08.159.
• Hanratty, B., Holland, P., Jacoby, A., & Whitehead, M. (2007). Financial stress and strain associated with terminal cancer-A review of the evidence. Palliative Medicine, 21(7), 595-607.
• Hoang, V. M., Pham, C. P., Vu, Q. M., Ngo, T. T., Tran, D. H., Bui, D., Pham, X. D., Tran, D. K., & Mai, T. K. (2017). Household financial burden and poverty impacts of cancer treatment in Vietnam. BioMed Research International, 2017:9350147. doi: 10.1155/2017/9350147.
• Hofstatter, E. W. (2010). Understanding patient perspectives on communication about the cost of cancer care: A review of the literature. Journal of Oncology Practice, 6(4), 188-192.
• Honda, K., Gyawali, B., Ando, M., Sugiyama, K., Mitani, S., Masuishi, T., Narita, Y., Taniguchi, H., Kadowaki, S., Ura, T., & Muro, K. (2018). A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: Report on a pilot study. ecancermedicalscience, 12:847. doi: 10.3332/ecancer.2018.847.
• Honda, K., Gyawali, B., Ando, M., Kumanishi, R., Kato, K., Sugiyama, K., Mitani, S., Masuishi, T., Narita, Y., Bando, H., Taniguchi, H., Kadowaki, S., Ura, T., & Muro, K. (2019). Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer. J Global Oncol, 5, 1-8.
• Huyard, C., Derijks, L., Haak, H., & Lieverse, L. (2017). Intentional nonadherence as a means to exert control. Qualitative Health Research, 27(8), 1215-1224.
• Imber, B. S., Varghese, M., Ehdaie, B., & Gorovets, D. (2020). Financial toxicity associated with treatment of localized prostate cancer. Nature Reviews Urology, 17(1), 28-40.
• Institute of Medicine and National Research Council. (2006). From cancer patient to cancer survivor: Lost in transition. The National Academies Press, Washington, DC.
• Jacob, J., Palat, G., Verghese, N., Chandran, P., Rapelli, V., Kumari, S., Malhotra, C., Teo, I., Finkelstein, E., & Ozdemir, S. (2019). Health-related quality of life and its socio-economic and cultural predictors among advanced cancer patients: Evidence form the APPROACH cross-sectional survey in Hyderabad-India. BMC Palliative Care, 18(1):94. doi: 10.1186/s12904-019-0465-y.
• Jagsi, R., Pottow, J. A. E., Griffith, K. A., Bradley, C., Hamilton, A. S., Graff, J., Katz, S. J., & Hawley, S. T. (2014). Long-term financial burden of breast cancer: Experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol, 32(12), 1269-1276.
• Jing, J., Feng, R., Zhang, X., Li, M., & Gao, J. (2020). Financial toxicity and its associated patient and cancer factors among women with breast cancer: A single‑center analysis of low‑middle income region in China. Breast Cancer Research and Treatment, 181(2), 435-443.
• Kaser, E., Shaw, J., Marven, M., Swinburne, L., & Boyle, F. (2010). Communication about high-cost drugs in oncology-the patient view. Annals of Oncology, 21(9), 1910-1914.
• Kim, P. (2007). Cost of cancer care: The patient perspective. Journal of Clinical Oncology, 25(2), 228-232.
• Knight, T. G., Deal, A. M., Dusetzina, S. B., Muss, H. B., Choi, S. K., Bensen, J. T., & Williams, G. R. (2018). Financial toxicity in adults with cancer: Adverse outcomes and noncompliance. J Oncol Pract, 14(11), e665-e673.
• Kodama, Y., Morozumi, R., Matsumura, T., Kishi, Y., Murashige, N., Tanaka, Y., Takita, M., Hatanaka, N., Kusumi, E., Kami, M., & Matsui, A. (2012). Increased financial burden among patients chronic myelogenous leukaemia receiving imatinib in Japan: A retrospective survey. BMC Cancer, 12:152. doi: 10.1186/1471-2407-12-152.
• Kong, Y., Wong, L., Ng, C., Taib, N. A., Bhoo-Pathy, N. T., Yusof, M. M., Aziz, A. F., Yehgambaram, P., Ishak, W. Z. W., Yip, C., & Bhoo-Pathy, N. (2020). Understanding the financial needs following diagnosis of breast cancer in a setting with universal health coverage. The Oncologist, 25(6), 497–504.
• Langa, K. M., Fendrick, A. M., Chernew, M. E., Kabeto, M. U., Paisley, K. L., & Hayman, J. A. (2004). Out-of-pocket health-care expendiures among older Americans with cancer. Value in Health, 7(2), 186-194.
• Lentz, R., Benson, A. B., & Kircher, S. (2019). Financial toxicity in cancer care: Prevelance, causes, consequences, and reduction strategies. J Surg Oncol, 120(1), 85-92.
• Liang, M. I., & Huh, W. K. (2018). Financial toxicity-an overlooked side effects. Gynecologic Oncology, 150(1), 3-6.
• Longo, C. J., Fitch, M. I., Banfield, L., Hanly, P., Yabroff, K. R., & Sharp, L. (2020). Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: A systematic review. Supportive Care in Cancer, 28(10), 4645-4665.
• Lu, L., O’Sullivan, E., & Sharp, L. (2019). Cancer-related financial hardship among head and neck cancer survivors: Risk factors and associations with health-related quality of life. Psycho-Oncology, 28(4), 863-871.
• Macmillan Cancer Support (2006). Cancer’s hidden price tag: Revealing the costs behind the illness.
• McDermott, C. (2017). Financial toxicity: A common but rarely discussed treatment side effect. Ann Am Thorac Soc, 14(12), 1750-1752.
• McDougall, J. A., Ramsey, S. D., Hutchinson, F. & Shih, Y. T. (2014). Financial toxicity: A growing concern among cancer patients in the United States. ISPOR Connections, 20(2), 10-11.
• McNulty, J., & Khera, N. (2015). Financial hardship-an unwanted consequence of cancer treatment. Curr Hematol Malig Rep, 10(3), 205-212.
• Meeker, C. R., Geynisman, D. M., Egleston, B. L., Hall, M., J., Mechanic, K. Y., Bilusic, M., Plimack, E. R., Martin, L. P., von Mehren, M., Lewis, B., & Wong, Y. (2016). Relationships among financial distress, emotional distress, and overall distress in insured patients with cancer. Journal of Oncology Practice, 12(7), e755-e764.
• Meeker, C. R., Wong, Y., Egleston, B. L., Hall, M. J., Plimack, E. R., Martin, L. P., von Mehren, M., Lewis, B. R., & Geynisman, D. M. (2017). Distress and financial distress in adults with cancer: An age-based analysis. J Natl Compr Canc Netw, 15(10), 1224-1233.
• Meisenberg, B. R., Varner, A., Ellis, E., Ebner, S., Moxley, J., Siegrist, E., & Weng, D., (2015). Patient attitudes regarding the cost of illness in cancer care. The Oncologist, 20(10), 1199-1204.
• Mohanti, B. K., Mukhopadhyay, A., Das, S., Sharma, K., & Dash, S. (2011). Estimating the economic burden of cancer at a tertiary public hospital: A study at the all India Institute of Medical Sciences. Discussion Paper:11-09. Indian Statistical Institute, New Delhi, India.
• Morel, H. L. (2018). Advanced cancer patients’ medical decision-making while experiencing financial toxicity. Walden University, College of Health Sciences.
• Nelson, B. (2019). A growing side effect of cancer care: Financial toxicity. Cancer Cytopathology, 127(11), 673-674.
• O’Connor, J. M., Kircher, S., & de Souza, J. A. (2016). Financial toxicity in cancer care. The Journal of Community and Supportive Oncology, 14(3), 101-106. Oxford Advanced Learner’s Dictionary (2010). Oxford advanced learner’s dictionary of current english (8th ed.). Oxford University Press.
• Özmen, V. (2018). A patient advocacy group summit, cancer care in Turkey and the society of breast health. Eur J Breast Health, 14(1), 1-4.
• Park, J., & Look, K. A. (2018). Relationship between objective financial burden and the health-related quality of life and mental health of patients with cancer. Journal of Oncology Practice, 14(2), e113-e121.
• Pearce, A., Tomalin, B., Kaambwa, B., Horevoorts, N., Dujits, S., Mols, F., van de Poll-Franse, L., & Koczwara, B. (2019). Financial toxicity is more than costs of care: The relationship between employment and financial toxicity in long-term cancer survivors. Journal of Cancer Survivorship, 13(1), 10-20.
• Perrone, F., Jommi, C., Di Maio, M., Gimigliano, A., Gridelli, C., Pignata, S., Ciardiello, F., Nuzzo, F., de Matteis, A., Del Mastro, L., Bryce, J., Daniele, G., Morabito, A., Piccirillo, M. C., Rocco, G., Guizzaro, L., & Gallo, C. (2016). The association of financial difficulties with clinical outcomes in cancer patients: Secondary analysis of 16 academic prospective clinical trials conducted in Italy. Annals of Oncology, 27(12), 2224-2229.
• Philips, F., Kvale, E., Jones, B., Currin-Mcculloch, J., & Byelousova, A. (2019). The construct of financial toxicity and association with quality of life in poor populations (TH341A). Journal of Pain and Symptom Management, 57(2), 386.
• Public Sector Consultants (2018). Financial navigation for people undergoing cancer treatment. Michigan Cancer Consortium. https://michigancancer.org adresinden 01.09.2020 tarihinde erişilmiştir.
• Ramsey, S. D., Blough, D. K., Kirchhoff, A. C., Fedorenko, C. R., Snell, K. S., Kreizenbeck, K. L. Newcomb, P., Hollingworth, W, & Ovestreet, K. A. (2013). Washington cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff, 32(6), 1143-1152.
• Ratain, M. J. (2009). Biomarkers and clinical care. Presented at the AAAS/FDLI Colloquium, Personalized Medicine in an Era of Health Care Reform, Washington, DC.
• Ripamonti, C. I., Chiesi, F., Pede, P. D., Guglielmo, M., Toffolatti, L., Gangeri, L., & Allocca, E. (2020). The validation of the Italian version of the comprehensive score for financial toxicity (COST). Supportive Care in Cancer, 28(9), 4477-4485.
• Rosenzweig, M., West, M., Matthews, J., Stokan, M., Kook, Y., Gallups, S., & Diergaarde, B. (2019). Financial toxicity among women with metastatic breast cancer. Oncology Nursing Forum, 46(1), 83-91.
• Rotter, J., Spencer, J. C., 6 Wheeler, S. B. (2019). Financial toxicity in advanced and metastatic cancer: Overburdened and underprepared. J Oncol Pract, 15(4), e300-e307.
• Sağlık Uygulama Tebliği (SUT). (2020). 16.06.2020 değişiklik tebliği işlenmiş güncel 2013 SUT. http://www.sgk.gov.tr adresinden 15.09.2020 tarihinde erişilmiştir.
• SASAM Enstitüsü (2016). Sağlık sisteminin güçlendirilmesi (Odak grup görüşmeleri raporu). Ankara: Sağlık-Sen Yayınları-36.
• Shankaran, V., & Ramsey, S. (2015). Addressing the financial burden of cancer treatment from copay to can’t pay. JAMA Oncology, 1(3), 273-274.
• Sharp, L., & Timmons, A. (2010). The financial impact of a cancer diagnosis. National Cancer Registry/Irish Cancer Society.
• Siminoff, L. A., & Ross, L. (2005). Access and equity to cancer care in the USA: A review and assessment. Postgrad Med, 81(961), 674-679.
• Singleterry, J. (2017). The costs of cancer: Addressing patient costs. American Cancer Society Cancer Action Network.
• Snyder, R. A., & Chang, G. J. (2019). Financial toxicity: A growing burden of cancer patients. Bulletin of the American College of Surgeons, 104(9), 38-43.
• Sosyal Güvenlik Kurumu (SGK). (2012). Sosyal Güvenlik Kurumu aylık bülteni sigortalı istatistikleri, Ocak 2012. http://www.sgk.gov.tr/ adresinden 01.08.2020 tarihinde erişilmiştir.
• Sosyal Güvenlik Kurumu (SGK) (2015). 01.12.2015 tarihli basın açıklaması: Kemoterapi ilaçları. T. C. Sosyal Güvenlik Kurumu Başkanlığı Basın ve Halkla İlişkiler Müşavirliği. 01.09.2020 tarihinde erişilmiştir.
• Sosyal Güvenlik Kurumu (SGK). (2020). Sosyal Güvenlik Kurumu Aylık Bülteni Sigortalı İstatistikleri, Ocak 2020. http://www.sgk.gov.tr/ adresinden 01.09.2020 tarihinde erişilmiştir.
• Sosyal Güvenlik Kurumu Sağlık Uygulama Tebliğinde Değişiklik Yapılmasına Dair Tebliğ. (2018). Resmi Gazete, 30469, 5 Temmuz 2018.
• Tatar, M., & Tatar, F. (2010). Colorectal cancer in Turkey: Current situation and challenges for the future. Eur J Health Econ, 10(Suppl 1), 99-105.
• T.C. Aile, Çalışma ve Sosyal Hizmetler Bakanlığı (2021). SGK 2020 yılında ilaç için 48,6 milyar lira kaynak aktardı. https://www.ailevecalisma.gov.tr/ adresinden 01.03.2021 tarihinde erişilmiştir.
• T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü (2018). 4 şubat dünya kanser günü. https://hsgm.saglik.gov.tr/ adresinden 01.09.2020 tarihinde erişilmiştir.
• The Action Study Group. (2015a). Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: Results from a longitudinal study in eight countries. BMC Medicine, 13:190. https://doi.org/10.1186/s12916-015-0433-1.
• The Action Study Group. (2015b). Financial catastrophe, treatment discontinuation and death associated with surgically operable cancer in South-East Asia: Results from the ACTION study. Surgery, 157(6), 971-982.
• Thom, B., & Benedict, C. (2019). The impact of financial toxicity on psychological well-being, coping self-efficacy, and cost-coping behaviors in young adults with cancer. Journal of Adolescent and Young Adult Oncology, 8(3), 236–242.
• Ting, C. Y., Teh, G. C., Yu, K. L., Alias, H., Tan, H. M., & Wong, L. P. (2020). Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country. Supportive Care in Cancer Care 28(4), 1703-1715.
• Tran, G., & Zafar, S. Y. (2018a). Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Annals of Translational Medicine, 6(9):166. doi: 10.21037/atm.2018.03.28.
• Tran, G., & Zafar, S. Y. (2018b). Price of cancer care and its tax on quality of life. Journal of Oncology Practice, 14(2), 69-71.
• Tucker-Seeley, R. D., & Yabroff, K. R. (2016). Minimizing the “financial toxicity” associated with cancer care: Advancing the research agenda. J Natl Cancer Inst, 108(5), 1-3.
• Türkiye İstatistik Kurumu (2013). Sağlık harcamaları istatistikleri 2009-2012. https://data.tuik.gov.tr/tr/ adresinden 01.09.2020 tarihinde erişilmiştir.
• Türkiye İstatistik Kurumu (2014). Sağlık harcamaları istatistikleri 2013. https://data.tuik.gov.tr/tr/ adresinden 01.09.2020 tarihinde erişilmiştir.
• Türkiye İstatistik Kurumu (2016). Sağlık harcamaları istatistikleri 2015. https://data.tuik.gov.tr/tr/ adresinden 01.09.2020 tarihinde erişilmiştir.
• Türkiye İstatistik Kurumu (2018). Sağlık harcamaları istatistikleri 2017. https://data.tuik.gov.tr/tr/ adresinden 01.09.2020 tarihinde erişilmiştir.
• Türkiye İstatistik Kurumu (2020). Sağlık harcamaları istatistikleri 2019. https://data.tuik.gov.tr/tr/ adresinden 01.09.2020 tarihinde erişilmiştir.
• Uğurluoğlu, Ö., Ürek, D., & Bilgin Demir, İ. (2019). Evaluation of individuals’ satisfaction with health care services in Turkey. Health Policy and Technology, 8(1), 24-29.
• Wan, N. C., Hairi, N. N. M., Jenn, N. C., & Kamarulzaman, A. (2014). Universal health coverage in Malaysia: Issues and challenges. http://familyrepository.lppkn.gov.my/399/4/Universal_health_ coverage_in_Malaysia_-_Full_Paper.pdf.
• Williams, C. P., Pisu, M., Azuero, A., Kenzik, K. M., Nipp, R. D., Aswani, M. S., Mennemeyer, S. T., Pierce, J. Y., & Rocque, G. B. (2020). Health insurance literacy and financial hardship in women living with metastatic breast cancer. JCO Oncol Pract, 16(6), e529-e537.
• Wright, J. D. (2019). Financial toxicity: A severe but underrecognized side effect for cancer patients. Gynecologic Oncology, 154(1), 1-2.
• Yabroff, K. R., Lund, J., Kepka, D., & Mariotto, A. (2011). Economic burden of cancer in the United States: Estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev, 20(10), 2006-2014.
• Zafar, S. Y., & Abernethy, A. P. (2013). Financial toxicity, part II: How can we help with the burden of treatment-related costs?. Oncology, 27(4), 253-256.
• Zafar, S. Y., Peppercorn, J. M., Schrag, D., Taylor, D. H., Goetzinger, A. M., Zhong, X., & Abernethy, A. P. (2013). The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. The Oncologist, 18(4), 381-390.
• Zafar, S. Y., McNeil, R. B., Thomas, C. M., Lathan, C. S., Ayanian, J. Z., & Provenzale, D. (2015). Population-based assessment of cancer survivors’ financial burden and quality of life: A prospective cohort study. Journal of Oncology Practice, 11(2), 145-150.
• Zafar, S. Y. (2016). Financial toxicity of cancer care: It’s time to intervene. J Natl Cancer Inst, 108(5): djv370. doi: 10.1093/jnci/djv370.
• Zhu, Z., Xing, W., Lizarondo, L., Peng, J., Hu, Y., & So, W. K. (2020). Psychometric properties of self-reported financial toxicity measures in cancer survivors: A systematic review protocol using COSMIN Methodology. BMJ Open, 10:e036365. doi: 10.1136/bmjopen-2019-036365.